Lamivudine for treatment of spontaneous exacerbation and reactivation after immunosuppressive therapy in patients with hepatitis B virus infection.
We evaluated the efficacy of lamivudine therapy for treatment of spontaneous exacerbation and reactivation after immunosuppressive therapy in patients with hepatitis B virus infection. Lamivudine is an effective therapy if used in early stages of both spontaneous exacerbation and reactivation after immunosuppressive therapy. In our study, twelve patients experienced flares of chronic hepatitis B over a three-year period. Three patients whose pretreatment total bilirubin levels were more than 7mg/dL died of fatal liver failure despite lamivudine therapy. We concluded that if pretreatment serum bilirubin levels are higher than 7 mg/dL, lamivudine therapy alone may be insufficient and more effective therapies should be considered concomitantly with lamivudine.